Table 2 Baseline clinical characteristics of RACER cohort segregated by RA disease activity
All | Total n, % | High DAa, n, % | Low DA n, % | Chi-square p-value |
|---|---|---|---|---|
729, 100% | 326, 45% | 403, 55% | ||
CRP: Abnormal | 241, 33% | 170, 52% | 71, 18% | < 0.0001* |
Disease duration | ||||
0–2 years | 114, 16% | 61, 19% | 53, 13% | |
> 2 and < 10 years | 253, 35% | 98, 30% | 155, 38% | |
> 10 years | 360, 49% | 167, 51% | 193, 48% | 0.0221* |
Medication current use | ||||
Methotrexate | 720, 98.8% | 323, 99% | 397, 99% | 0.449 |
Leflunomide | 72, 10% | 35, 11% | 37, 9% | NA |
Biologic agent | 275, 38% | 95, 29% | 180, 45% | 1 |
Steroid | 720, 98.8% | 323, 99% | 397, 99% | 0.449 |
n, median (IQR) | Wilcoxon p-value | |||
RF | 683, 44 (20, 191) | 305, 63 (21, 345) | 378, 36 (20, 136) | 0.0002* |
Anti-CCPb | 728, 41 (2, 206.5) | 326, 45.3 (2, 224) | 402, 35 (2, 196) | 0.3972 |
IL-6 | 694, 2 (2, 9) | 311, 5 (2, 12.3) | 383, 2 (2, 6.4) | < .0001* |